October 1st was a significant day in the Zofran (ondansetron) litigation, as the Judicial Panel on Multidistrict Litigation met to consider the arguments for consolidating several lawsuits against the anti-nausea drug’s manufacturer, GlaxoSmithKline (“GSK”). The ruling will be the first big step in the litigation, as plaintiffs are vying to have their cases centralized before …. Read More
At the forefront of the Zofran (ondansetron) litigation since its inception, law firm Grant & Eisenhofer has filed one of the latest Zofran (ondansetron) lawsuits in the Eastern District of Louisiana on behalf of Alexis Alexander and her son who was born with birth defects. The suit alleges that GlaxoSmithKline, maker of Zofran (ondansetron), marketed the …. Read More
GlaxoSmithKline (“GSK”), maker of anti-nausea drug Zofran (ondansetron), has filed a request with the U.S. Judicial Panel on Multidistrict Litigation asking it to consolidate a dozen lawsuits pending against GSK in ten judicial districts across the country—including three suits filed by Grant & Eisenhofer, the first law firm to file a Zofran (ondansetron) birth defect …. Read More
